BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

127 related articles for article (PubMed ID: 25104793)

  • 1. High-throughput screening of human leukemia xenografts to identify dexamethasone sensitizers.
    Toscan CE; Failes T; Arndt GM; Lock RB
    J Biomol Screen; 2014 Dec; 19(10):1391-401. PubMed ID: 25104793
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Thioimidazoline based compounds reverse glucocorticoid resistance in human acute lymphoblastic leukemia xenografts.
    Toscan CE; Rahimi M; Bhadbhade M; Pickford R; McAlpine SR; Lock RB
    Org Biomol Chem; 2015 Jun; 13(22):6299-312. PubMed ID: 25967739
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Reversal of glucocorticoid resistance in paediatric acute lymphoblastic leukaemia is dependent on restoring BIM expression.
    Toscan CE; Jing D; Mayoh C; Lock RB
    Br J Cancer; 2020 Jun; 122(12):1769-1781. PubMed ID: 32242100
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Divergent mechanisms of glucocorticoid resistance in experimental models of pediatric acute lymphoblastic leukemia.
    Bachmann PS; Gorman R; Papa RA; Bardell JE; Ford J; Kees UR; Marshall GM; Lock RB
    Cancer Res; 2007 May; 67(9):4482-90. PubMed ID: 17483364
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The anti-CD19 antibody-drug conjugate SAR3419 prevents hematolymphoid relapse postinduction therapy in preclinical models of pediatric acute lymphoblastic leukemia.
    Carol H; Szymanska B; Evans K; Boehm I; Houghton PJ; Smith MA; Lock RB
    Clin Cancer Res; 2013 Apr; 19(7):1795-805. PubMed ID: 23426279
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A pre-clinical model of resistance to induction therapy in pediatric acute lymphoblastic leukemia.
    Samuels AL; Beesley AH; Yadav BD; Papa RA; Sutton R; Anderson D; Marshall GM; Cole CH; Kees UR; Lock RB
    Blood Cancer J; 2014 Aug; 4(8):e232. PubMed ID: 25083816
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Preclinical activity of LBH589 alone or in combination with chemotherapy in a xenogeneic mouse model of human acute lymphoblastic leukemia.
    Vilas-Zornoza A; Agirre X; Abizanda G; Moreno C; Segura V; De Martino Rodriguez A; José-Eneriz ES; Miranda E; Martín-Subero JI; Garate L; Blanco-Prieto MJ; García de Jalón JA; Rio P; Rifón J; Cigudosa JC; Martinez-Climent JA; Román-Gómez J; Calasanz MJ; Ribera JM; Prósper F
    Leukemia; 2012 Jul; 26(7):1517-26. PubMed ID: 22307227
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Dexamethasone resistance in B-cell precursor childhood acute lymphoblastic leukemia occurs downstream of ligand-induced nuclear translocation of the glucocorticoid receptor.
    Bachmann PS; Gorman R; Mackenzie KL; Lutze-Mann L; Lock RB
    Blood; 2005 Mar; 105(6):2519-26. PubMed ID: 15572593
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Heterogeneity in mechanisms of emergent resistance in pediatric T-cell acute lymphoblastic leukemia.
    Yadav BD; Samuels AL; Wells JE; Sutton R; Venn NC; Bendak K; Anderson D; Marshall GM; Cole CH; Beesley AH; Kees UR; Lock RB
    Oncotarget; 2016 Sep; 7(37):58728-42. PubMed ID: 27623214
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The Bcl-2 homology domain 3 mimetic ABT-737 targets the apoptotic machinery in acute lymphoblastic leukemia resulting in synergistic in vitro and in vivo interactions with established drugs.
    High LM; Szymanska B; Wilczynska-Kalak U; Barber N; O'Brien R; Khaw SL; Vikstrom IB; Roberts AW; Lock RB
    Mol Pharmacol; 2010 Mar; 77(3):483-94. PubMed ID: 20038611
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A role for altered microtubule polymer levels in vincristine resistance of childhood acute lymphoblastic leukemia xenografts.
    Ong V; Liem NL; Schmid MA; Verrills NM; Papa RA; Marshall GM; Mackenzie KL; Kavallaris M; Lock RB
    J Pharmacol Exp Ther; 2008 Feb; 324(2):434-42. PubMed ID: 17986648
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Enhancement of the in vivo antitumor activity of clofarabine by 1-beta-D-[4-thio-arabinofuranosyl]-cytosine.
    Parker WB; Shaddix SC; Gilbert KS; Shepherd RV; Waud WR
    Cancer Chemother Pharmacol; 2009 Jul; 64(2):253-61. PubMed ID: 19002461
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Combination of prednisolone and low dosed dexamethasone exhibits greater in vitro antileukemic activity than equiactive dose of prednisolone and overcomes prednisolone drug resistance in acute childhood lymphoblastic leukemia.
    Spenerova M; Dzubak P; Srovnal J; Radova L; Burianova R; Konecny P; Salkova S; Novak Z; Pospisilova D; Stary J; Blazek B; Hak J; Votava T; Timr P; Kaiserova E; Bubanska E; Mihal V; Hajduch M
    Biomed Pap Med Fac Univ Palacky Olomouc Czech Repub; 2014 Sep; 158(3):422-7. PubMed ID: 23128824
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Pharmacokinetic modeling of an induction regimen for in vivo combined testing of novel drugs against pediatric acute lymphoblastic leukemia xenografts.
    Szymanska B; Wilczynska-Kalak U; Kang MH; Liem NL; Carol H; Boehm I; Groepper D; Reynolds CP; Stewart CF; Lock RB
    PLoS One; 2012; 7(3):e33894. PubMed ID: 22479469
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Antileukemic Efficacy of Continuous vs Discontinuous Dexamethasone in Murine Models of Acute Lymphoblastic Leukemia.
    Ramsey LB; Janke LJ; Payton MA; Cai X; Paugh SW; Karol SE; Kamdem Kamdem L; Cheng C; Williams RT; Jeha S; Pui CH; Evans WE; Relling MV
    PLoS One; 2015; 10(8):e0135134. PubMed ID: 26252865
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The XPO1 Inhibitor KPT-8602 Synergizes with Dexamethasone in Acute Lymphoblastic Leukemia.
    Verbeke D; Demeyer S; Prieto C; de Bock CE; De Bie J; Gielen O; Jacobs K; Mentens N; Verhoeven BM; Uyttebroeck A; Boeckx N; De Keersmaecker K; Maertens J; Segers H; Cools J
    Clin Cancer Res; 2020 Nov; 26(21):5747-5758. PubMed ID: 32826328
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Variegated clonality and rapid emergence of new molecular lesions in xenografts of acute lymphoblastic leukemia are associated with drug resistance.
    Nowak D; Liem NL; Mossner M; Klaumünzer M; Papa RA; Nowak V; Jann JC; Akagi T; Kawamata N; Okamoto R; Thoennissen NH; Kato M; Sanada M; Hofmann WK; Ogawa S; Marshall GM; Lock RB; Koeffler HP
    Exp Hematol; 2015 Jan; 43(1):32-43.e1-35. PubMed ID: 25450514
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Circumvention of glucocorticoid resistance in childhood leukemia.
    Haarman EG; Kaspers GJ; Pieters R; Rottier MM; Veerman AJ
    Leuk Res; 2008 Sep; 32(9):1417-23. PubMed ID: 18395253
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Important role of caspase-8 for chemosensitivity of ALL cells.
    Ehrhardt H; Wachter F; Maurer M; Stahnke K; Jeremias I
    Clin Cancer Res; 2011 Dec; 17(24):7605-13. PubMed ID: 22010212
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Preclinical activity of the antibody-drug conjugate denintuzumab mafodotin (SGN-CD19A) against pediatric acute lymphoblastic leukemia xenografts.
    Jones L; McCalmont H; Evans K; Mayoh C; Kurmasheva RT; Billups CA; Houghton PJ; Smith MA; Lock RB
    Pediatr Blood Cancer; 2019 Aug; 66(8):e27765. PubMed ID: 31012549
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.